Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | -139,674 | -256,256 | -284,126 | -227,006 | -147,722 |
Depreciation Amortization | -7,872 | 1,103 | -3,547 | -120 | -655 |
Accounts receivable | -38,829 | -55,033 | -9,391 | -10,765 | N/A |
Accounts payable and accrued liabilities | 1,057 | 1,704 | 3,189 | -1,923 | -6,536 |
Other Working Capital | -29,577 | -58,136 | -6,353 | -27,276 | -590 |
Other Operating Activity | 90,696 | 96,432 | 40,684 | 37,017 | 27,519 |
Operating Cash Flow | $-124,199 | $-270,186 | $-259,544 | $-230,073 | $-127,983 |
Cash Flows From Investing Activities | |||||
PPE Investments | -269 | -778 | -325 | -267 | -700 |
Purchase Of Investment | -415,269 | -759,209 | -224,575 | -755,629 | -80,720 |
Sale Of Investment | 521,079 | 631,614 | 505,244 | 275,601 | 258,858 |
Investing Cash Flow | $105,541 | $-128,373 | $280,344 | $-480,295 | $177,437 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | 17,810 | 455,159 | 11,519 | 664,177 | 3,236 |
Financing Cash Flow | $17,810 | $455,159 | $11,519 | $664,177 | $3,236 |
Beginning Cash Position | 150,365 | 93,765 | 61,446 | 107,637 | 54,948 |
End Cash Position | 149,517 | 150,365 | 93,765 | 61,446 | 107,637 |
Net Cash Flow | $-848 | $56,600 | $32,319 | $-46,191 | $52,689 |
Free Cash Flow | |||||
Operating Cash Flow | -124,199 | -270,186 | -259,544 | -230,073 | -127,983 |
Capital Expenditure | -269 | -778 | -325 | -267 | -700 |
Free Cash Flow | -124,468 | -270,964 | -259,869 | -230,340 | -128,684 |